Fig. 2.

A higher level of lncSNHG15 in TMZ resistant GBM cells and associated with GBM malignancy (a) Comparative lncSNHG15 expression between TMZ resistant and sensitive clinical GBM samples. Real-time PCR analysis showed that a significantly higher level of lncSNGH15 in samples from patients who are non-responsive towards TMZ as compared to ones with responsiveness. TMZ-resistant cells showed an enhanced colony (b) and neurosphere (c) forming ability over TMZ-sensitive counterparts. d Comparative flow cytometric analysis also showed that TMZ-R cells contained a significantly higher percentages of CD133+ population (approximately 30% more) than their TMZ-S counterparts. e Comparative qPCR and western blot analysis of TMZ-resistant and TMZ-sensitive GBM cells. The lncSNHG15 was significantly higher in the TMZ-R cells as compared to TMZ-S cells. Also, the expression of stemness markers, Sox2, β-catenin and oncogenic markers EGFR and CDK6 were significantly lower in the TMZ-sensitive cells as compared to its TMZ-resistant counterpart. Neural differentiation marker GFAP was slightly higher in the TMZ-sensitive GBM cells